These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
437 related items for PubMed ID: 9748351
1. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. Campiani G, Nacci V, Bechelli S, Ciani SM, Garofalo A, Fiorini I, Wikström H, de Boer P, Liao Y, Tepper PG, Cagnotto A, Mennini T. J Med Chem; 1998 Sep 24; 41(20):3763-72. PubMed ID: 9748351 [Abstract] [Full Text] [Related]
2. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P. J Med Chem; 2004 Jan 01; 47(1):143-57. PubMed ID: 14695828 [Abstract] [Full Text] [Related]
5. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA. J Pharmacol Exp Ther; 1995 Oct 01; 275(1):101-13. PubMed ID: 7562537 [Abstract] [Full Text] [Related]
6. New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation. Liao Y, Venhuis BJ, Rodenhuis N, Timmerman W, Wikström H, Meier E, Bartoszyk GD, Böttcher H, Seyfried CA, Sundell S. J Med Chem; 1999 Jun 17; 42(12):2235-44. PubMed ID: 10377229 [Abstract] [Full Text] [Related]
7. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, Pasteau V, Boutin JA, Dubuffet T, Lavielle G. J Pharmacol Exp Ther; 2008 Feb 17; 324(2):587-99. PubMed ID: 18024789 [Abstract] [Full Text] [Related]
8. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL. J Pharmacol Exp Ther; 1998 Oct 17; 287(1):167-86. PubMed ID: 9765336 [Abstract] [Full Text] [Related]
11. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, Cagnotto A, Fumagalli E, Carnovali F, Cervo L, Mennini T. J Med Chem; 2003 Aug 28; 46(18):3822-39. PubMed ID: 12930145 [Abstract] [Full Text] [Related]
13. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. J Pharmacol Exp Ther; 1997 Jan 28; 280(1):73-82. PubMed ID: 8996184 [Abstract] [Full Text] [Related]
14. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Ohno Y, Ishida-Tokuda K, Ishibashi T, Sakamoto H, Tagashira R, Horisawa T, Yabuuti K, Matsumoto K, Kawabe A, Nakamura M. Pol J Pharmacol; 1997 Aug 28; 49(4):213-9. PubMed ID: 9437764 [Abstract] [Full Text] [Related]
15. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Leysen JE, Janssen PM, Megens AA, Schotte A. J Clin Psychiatry; 1994 May 28; 55 Suppl():5-12. PubMed ID: 7520908 [Abstract] [Full Text] [Related]
16. Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding. Metwally KA, Dukat M, Egan CT, Smith C, DuPre A, Gauthier CB, Herrick-Davis K, Teitler M, Glennon RA. J Med Chem; 1998 Dec 03; 41(25):5084-93. PubMed ID: 9836624 [Abstract] [Full Text] [Related]
17. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Zhang W, Bymaster FP. Psychopharmacology (Berl); 1999 Jan 03; 141(3):267-78. PubMed ID: 10027508 [Abstract] [Full Text] [Related]
18. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds. Ohmori J, Maeno K, Hidaka K, Nakato K, Matsumoto M, Tada S, Hattori H, Sakamoto S, Tsukamoto S, Usuda S, Mase T. J Med Chem; 1996 Jul 05; 39(14):2764-72. PubMed ID: 8709107 [Abstract] [Full Text] [Related]
19. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY. J Pharmacol Exp Ther; 1993 Sep 05; 266(3):1374-84. PubMed ID: 8103793 [Abstract] [Full Text] [Related]
20. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia. Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY. Pharmacol Biochem Behav; 2005 Oct 05; 82(2):361-72. PubMed ID: 16216322 [Abstract] [Full Text] [Related] Page: [Next] [New Search]